Burrill Report: Biotech Innovation Gets the Cash
If the past week is any indication, big pharma is showing that it is willing to pay for biotech innovation.
cellerix
Cellular Reprogramming May Offer Stem-Cell Compromise
President Obama’s recent reversal of Bush’s policy on embryonic stem cell research reignited the debate over the ethical limits of science. However, as the Wall Street Journal reports, an innovative new technique could potentially reproduce the benefits of embryonic stem cells without the attendant controversy.